C. Sanchez
Hospital Universitario La Paz
17 Papers
249 Citations
C. Sanchez is an academic researcher from Hospital Universitario La Paz. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 9, co-authored 12 publications.
Chat about Author
Papers
Immunogenicity and safety of an adjuvanted hepatitis B vaccine in pre-hemodialysis and hemodialysis patients
Norella Kong Chiew Tong,Jiri Beran,Swee Ann Kee,Jose Luis Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,J R de Juanes,P. Arrazola,Francisco Calbo-Torrecillas,Eduardo López de Novales,Virginie Hamtiaux,Marc Lievens,Michel Stoffel +13 more
TL;DR: The improved immunogenicity profile and clinically acceptable reactogenicity of HB-AS04 vaccine are of key importance to provide a more rapid, enhanced, and longer seroprotection to these immunocompromised patients at risk for HB infection.
215
Anorexigen (TNF-alpha, cholecystokinin) and orexigen (neuropeptide Y) plasma levels in peritoneal dialysis (PD) patients: their relationship with nutritional parameters.
TL;DR: The data suggest that high TNF-alpha and low NPY serum levels are associated with anorexia and malnutrition among 55 clinically stable peritoneal dialysis patients and are also related to a poor nutritional status.
123
Immunogenicity, reactogenicity and safety of an inactivated quadrivalent influenza vaccine candidate versus inactivated trivalent influenza vaccine: a phase III, randomized trial in adults aged ≥18 years
Dorothee Kieninger,Eric Sheldon,Wen-Yuan Lin,Chong-Jen Yu,José M. Bayas,Julian J. Gabor,Meral Esen,Jose Luis Fernandez Roure,Silvia Narejos Perez,C. Sanchez,Yang Feng,Carine Claeys,Mathieu Peeters,Bruce L. Innis,Varsha K. Jain +14 more
TL;DR: QIV provided superior immunogenicity for the additional B strain compared with TIV, without interfering with antibody responses to the three shared antigens, suggesting that the candidate QIV is a viable alternative to TIV for use in adults, and could potentially improve protection against influenza B.
A new adjuvant improves the immune response to hepatitis B vaccine in hemodialysis patients
Norella C T Kong,Jiri Beran,S. A. Kee,J. L. Miguel,C. Sanchez,J.-M. Bayas,Anna Vilella,F. Calbo-Torrecillas,E. Lopez De Novales,Karthik Srinivasa,Michel Stoffel,Bernard Hoet +11 more
TL;DR: In this paper, the authors evaluated the immune response to the new adjuvant of hepatitis B vaccine AS04 (HBV-AS04) in prehemodialysis and hemodialysis patients.
82
Streptococcal versus Staphylococcus epidermidis peritonitis in CAPD. A comparative study
TL;DR: The aim of this study is to describe the episodes of streptococcal peritonitis that occurred in the peritoneal dialysis unit, in an effort to identify their peculiarities and potential risk factors.
25